Future Plans, Goals for Prime PD: Konstantin Karmazin, MD

Video

The chief medical officer of Prime PD, a new digital wellness studio for patients with Parkinson disease, detailed future initiatives for the platform. [WATCH TIME: 4 minutes]

WATCH TIME: 4 minutes

“In general, exercise is good for everybody, and the nervous system, in particular, really responds well. As evidence develops—hopefully over the next year or 2—we would be very open to MS [multiple sclerosis] exercise fitness programs and things like that.”

Prime PD offers the first digital wellness studio for those with Parkinson disease (PD), creating a personalized, virtual fitness program for this patient population. When signing up, patients can choose a subscription plan and access 8 different workout types, depending on independent patient needs and symptoms. We sat down with Konstantin Karmazin, MD, clinical neurologist and chief medical officer of Prime PD, to better understand the goals of the platform and plans to expand into other neurologic disease states.

In conversation with NeurologyLive®, Karmazin emphasized that while Prime PD’s current focus is on PD, they do intend to move into secondary chronic conditions such as dementia and mild cognitive impairment, as well as multiple sclerosis down the line. Additionally, there are plans to expand into a broader area of focus, incorporating nutrition into the overall package. Karmazin’s current focus lies with creating a pipeline for Prime PD and getting in touch with different health care professionals to establish relationships, he said. When sending patients with PD to a physical gym or boxing class, physicians are not able to ensure the quality of the workout in question or whether a patient actually attends, Karmazin added. With Prime PD, however, providers do have the ability to monitor patient progress, providing a trusted source of information that they can then assess.

Related Videos
Renã A. S. Robinson, PhD
Kevin Church, PhD
Merit Cudkowicz, MD, MSc
Jessica Ailani, MD
Frederic Schaper, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.